In­cyte inks $750M deal for im­mune and neu­ro biotech Escient

In­cyte said it will pay $750 mil­lion to buy San Diego biotech Escient Phar­ma­ceu­ti­cals and its pipeline of ear­ly-stage drug can­di­dates.

The deal gives the Delaware-based drug­mak­er ac­cess to once-dai­ly oral small mol­e­cules and the po­ten­tial to mar­ket new med­i­cines start­ing in 2029, In­cyte CEO Hervé Hop­penot said in a state­ment Tues­day morn­ing. In­cyte al­ready has eight ap­proved prod­ucts, in­clud­ing mul­ti-in­di­cat­ed Jakafi, blood can­cer med­i­cine Mon­ju­vi and eczema cream Opzelu­ra, among oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER